As new products enter the market, competition is expected to intensify, potentially leading to more affordable options for patients
Exenatide was approved by the US FDA in 2005 and by the European Medicines Agency (EMA) in 2006
Compounded drugs aren't reviewed by the FDA for safety or effectiveness before they're sold, and the agency had received more than 455 adverse event reports linked to compounded semaglutide as of early 2025, many involving dosing errors from multidose vials
Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium
Iodine deficiency causes thyroid disease (3,4)
Synergistic Botanical Complex The formulas carefully selected ingredients are designed to complement GLP-1 function, supporting appetite regulation, energy production, and overall metabolic wellness